Related Experiment Video
Updated: Aug 8, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease
Hua-Ping Dai1, Fei Ma2, Yan-Hong Ren3
1Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, 100029, China. daihuaping@ccmu.edu.cn.
Abstract:
Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse event of anticancer drugs. In recent years, the incidence of anticancer DILD has gradually increased with the rapid development of novel anticancer agents. Due to the diverse clinical manifestations and the lack of specific diagnostic criteria, DILD is difficult to diagnose and may even become fatal if not treated properly. Herein, a multidisciplinary group of experts from oncology, respiratory, imaging, pharmacology, pathology, and radiology departments in China has reached the "expert consensus on the diagnosis and treatment of anticancer DILD" after several rounds of a comprehensive investigation. This consensus aims to improve the awareness of clinicians and provide recommendations for the early screening, diagnosis, and treatment of anticancer DILD. This consensus also emphasizes the importance of multidisciplinary collaboration while managing DILD.
Insights
Anticancer drug-induced interstitial lung disease (DILD) is a growing concern. This expert consensus provides crucial recommendations for early screening, diagnosis, and treatment to improve patient outcomes.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
- Pathology
- Radiology
Background:
- Drug-induced interstitial lung disease (DILD) is the most frequent pulmonary complication associated with anticancer therapies.
- The incidence of DILD is rising due to the development of novel anticancer agents.
- DILD presents with varied clinical features and lacks specific diagnostic criteria, complicating early detection and management.
Purpose of the Study:
- To establish an expert consensus on the diagnosis and treatment of anticancer DILD.
- To enhance clinician awareness regarding anticancer DILD.
- To provide evidence-based recommendations for early screening, diagnosis, and treatment strategies.
Main Methods:
- A multidisciplinary expert group from China convened to develop the consensus.
- The consensus was formed after multiple rounds of comprehensive investigation and discussion.
- Key areas covered include screening, diagnosis, treatment, and the importance of collaborative care.
Main Results:
- The consensus offers a unified approach to managing DILD in patients receiving anticancer drugs.
- It highlights the need for improved diagnostic accuracy and timely intervention.
- Emphasis is placed on the critical role of multidisciplinary teams in managing DILD.
Conclusions:
- Early recognition and prompt management are vital for improving outcomes in anticancer DILD.
- Multidisciplinary collaboration is essential for effective DILD diagnosis and treatment.
- This consensus serves as a valuable resource for clinicians managing patients at risk of DILD.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...